Oppositional Defiant Disorder Completed Phase 3 Trials for Atomoxetine (DB00289)

Also known as: Conduct Disorder / Disruptive Behavior Disorders / Disruptive behaviour disorder / Disruptive Behavior Disorder / Conduct Disorders / Behavior Disorder, Disruptive / Conduct behavior disorder / Conduct behaviour disorder / Unspecified disturbance of conduct

IndicationStatusPhase
DBCOND0032311 (Oppositional Defiant Disorder)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00192023An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).Treatment
NCT00191698Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODDTreatment